Ethical analysis and countermeasures of artificial intelligence application in clinical trials
10.12092/j.issn.1009-2501.2022.03.012
- Author:
Xiaomin WANG
1
;
Xing LIU
2
;
Xiaoran LU
3
;
Ying WU
3
;
Haitao YU
3
Author Information
1. Clinical Trial Research Center, Clinical Pharmacology Center, the Third Xiangya Hospital of Central South University
2. Medical Ethics Committee of Xiangya Hospital, Hospital administration institute, Central South University
3. School of Public Administration, Central South University
- Publication Type:Journal Article
- Keywords:
Artificial intelligence;
Countermeasures and suggestions;
Drug clinical trials;
Ethical issues
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(3):322-327
- CountryChina
- Language:Chinese
-
Abstract:
The development of artificial intelligence is becoming more and more mature, and has penetrated into every field of clinical trials. Artificial intelligence has brought new development opportunities for clinical trials. However, the application of artificial intelligence in clinical trials is still in the exploratory stage, facing many ethical issues, including trial risk caused by data quality, privacy protection caused by data regulation, and contradiction between data authorization and informed consent. We should precisely position the realizable application of artificial intelligence in clinical trials, understand its practical ethical issues, and formulate corresponding coping strategies to ensure the maximum improvement of the whole process performance of clinical trials, including strengthening data quality management and reducing clinical trial risks; optimizing data monitoring mechanisms to ensure data security and privacy; building a data authorization platform and improving judicial protection of informed consent, etc.
